7th Annual Achieving Quality & Process Excellence in the Pharmaceutical Industry

Fleming Europe24 - 25 May 2011, Barcelona, Spain.
What are the new approaches to quality to achieve world-class manufacturing performance? How can you successfully introduce innovation and continual improvement into manufacturing?

Continuing pressures on life sciences manufacturing, from increased competition to regulatory requirements, are forcing organizations to achieve tighter operating efficiencies, while improving their ability to satisfy quality compliance standards.

Leading Pharma companies are now looking to Lean Manufacturing and Six Sigma principles to help them boost operational efficiency and improve quality. Explore the importance of six sigma in process validation and how to successfully apply Lean approach in Quality Assurance to simplify the processes.

Discuss with leading experts, how to build a sustainable quality culture during the times of change. Understand how to apply QbD tools during method development phase to achieve robust and reliable analytical procedures. Gain critical insights & first-hand experience how to incorporate risk management thinking and practices across the entire organization.

This event will bring together senior industry quality & operational excellence experts from the Pharmaceutical industry presenting real life case studies as well as a lot of networking sessions and discussions.

Key speakers:

  • Head of Quality Control, Sanofi Aventis, Germany
  • Senior Vice President Quality Assurance, Glenmark Pharmaceuticals, India
  • Head Operational Excellence & Lean, AstraZeneca, Sweden
  • Director Turbuhaler, AstraZeneca, Sweden
  • Quality Assurance Projects, Abbott, Italy
  • Head of Processes & Product Quality, Belupo, Croatia
  • More speakers to be announced

Key topics:

  • Explore Process Innovations for Operational Excellence
  • Enhance six sigma strategies to control costs, improve productivity and maintain compliance – how to integrate Quality & Operational Efficiency
  • Understand, how to link quality to performance
  • Reveal new approaches & tools for facilitating continuous improvement - building a sustainable quality culture and getting the right thinking across the entire organization
  • Maximize the benefits of QbD and Process understanding - best practices in QbD & PAT
  • Embrace Quality Risk Management - from theory to practice
  • Deployment of quality management for biologics - new challenges in aseptic processing of biologics
  • Understand new regulatory aspects of modern quality management and being prepared for the inspection

PLUS 3 Interactive Workshops:

  • Achieving efficiency in Quality Control
  • Application of Lean approach to Quality Assurance
  • Quality Risk Management - the new paradigm

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Quality Management, Quality Assurance, Quality Operations, Quality Control, Quality Systems, Regulatory Affairs, GMP Compliance, Quality by Design, PAT, Lean/Six Sigma, Lean Manufacturing, API manufacturing, Technical operations, Contract Manufacturing, Operational Excellence, Business Process Excellence, Operations, Production, Manufacturing, Supply Chain, Quality Risk Management, Qualified Person, Right First Time leaders.

For further information and registration, please visit:
http://flemingeurope.com/pharmaceuticals-conferences/europe/7th-annual-achieving-quality-process-excellence-in-the-pharmaceutical-industry

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Researchers call for worldwide biosurveillance net…

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding th...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

New study supports remdesivir as COVID-19 treatmen…

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies in the battle against COVI…

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have ...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...